BiotechTube

Tramadol /acetaminophen + Diclofenac

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Spondylitis, Ankylosing

Conditions

Spondylitis, Ankylosing, Pain

Trial Timeline

Oct 1, 2008 → Mar 1, 2009

NCT ID
NCT00766402

About Tramadol /acetaminophen + Diclofenac

Tramadol /acetaminophen + Diclofenac is a approved stage product being developed by Johnson & Johnson for Spondylitis, Ankylosing. The current trial status is terminated. This product is registered under clinical trial identifier NCT00766402. Target conditions include Spondylitis, Ankylosing, Pain.

What happened to similar drugs?

20 of 20 similar drugs in Spondylitis, Ankylosing were approved

Approved (20) Terminated (3) Active (0)
✅GolimumabJohnson & JohnsonApproved
✅InfliximabMerckApproved
✅GolimumabMerckApproved
✅RemicadeMerckApproved
✅RemicadeMerckApproved
✅InfliximabMerckApproved
✅InfliximabMerckApproved

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00766402ApprovedTerminated

Competing Products

20 competing products in Spondylitis, Ankylosing

See all competitors
ProductCompanyStageHype Score
InfliximabCelltrionPhase 1
29
InfliximabCelltrionPhase 1
29
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
adalimumabEisaiPhase 3
40
Ixekizumab + Placebo + AdalimumabEli LillyPhase 3
32
Golimumab + PlaceboJohnson & JohnsonPhase 3
40
GolimumabJohnson & JohnsonApproved
43
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 2/3
38
placebo for risankizumab + risankizumabAbbViePhase 2
35
Upadacitinib + PlaceboAbbViePhase 2
35
AdalimumabAbbViePre-clinical
26
infliximab + PlaceboMerckPhase 3
40
InfliximabMerckApproved
35
Infliximab + Placebo + NaproxenMerckPhase 3
40
InfliximabMerckPre-clinical
26
GolimumabMerckApproved
43
RemicadeMerckApproved
43
RemicadeMerckApproved
43
InfliximabMerckApproved
43
InfliximabMerckApproved
35